WO2001055408A1 - Ceramidase - Google Patents
Ceramidase Download PDFInfo
- Publication number
- WO2001055408A1 WO2001055408A1 PCT/EP2001/000900 EP0100900W WO0155408A1 WO 2001055408 A1 WO2001055408 A1 WO 2001055408A1 EP 0100900 W EP0100900 W EP 0100900W WO 0155408 A1 WO0155408 A1 WO 0155408A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ceramidase
- nucleic acid
- diseases
- seq
- defect
- Prior art date
Links
- 108090000751 Ceramidases Proteins 0.000 title claims abstract description 45
- 102000004201 Ceramidases Human genes 0.000 title claims abstract description 44
- 150000001413 amino acids Chemical class 0.000 claims abstract description 6
- -1 aromatic amino acid Chemical class 0.000 claims abstract description 4
- 229920001184 polypeptide Polymers 0.000 claims abstract description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 10
- 102000039446 nucleic acids Human genes 0.000 claims description 9
- 108020004707 nucleic acids Proteins 0.000 claims description 9
- 150000007523 nucleic acids Chemical class 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 230000007547 defect Effects 0.000 claims description 5
- 239000000032 diagnostic agent Substances 0.000 claims description 5
- 229940039227 diagnostic agent Drugs 0.000 claims description 5
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 claims description 4
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 claims description 4
- 229940106189 ceramide Drugs 0.000 claims description 4
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 claims description 4
- 239000002537 cosmetic Substances 0.000 claims description 4
- 238000003745 diagnosis Methods 0.000 claims description 4
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 claims description 4
- 206010021198 ichthyosis Diseases 0.000 claims description 3
- 230000002018 overexpression Effects 0.000 claims description 3
- 239000008177 pharmaceutical agent Substances 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 201000004624 Dermatitis Diseases 0.000 claims description 2
- 102100036621 Glucosylceramide transporter ABCA12 Human genes 0.000 claims description 2
- 101000929652 Homo sapiens Glucosylceramide transporter ABCA12 Proteins 0.000 claims description 2
- 208000001913 Lamellar ichthyosis Diseases 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 201000009053 Neurodermatitis Diseases 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 239000012190 activator Substances 0.000 claims description 2
- 208000010668 atopic eczema Diseases 0.000 claims description 2
- 201000000751 autosomal recessive congenital ichthyosis Diseases 0.000 claims description 2
- 201000001289 autosomal recessive congenital ichthyosis 4A Diseases 0.000 claims description 2
- 230000004888 barrier function Effects 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 230000004663 cell proliferation Effects 0.000 claims description 2
- 230000000295 complement effect Effects 0.000 claims description 2
- 230000007812 deficiency Effects 0.000 claims description 2
- 230000006806 disease prevention Effects 0.000 claims description 2
- 230000035699 permeability Effects 0.000 claims description 2
- 230000009261 transgenic effect Effects 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 1
- 239000002299 complementary DNA Substances 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000144 Human Proteins Proteins 0.000 description 3
- 102000003839 Human Proteins Human genes 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 102100025745 Cerberus Human genes 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 101000914195 Homo sapiens Cerberus Proteins 0.000 description 2
- 238000000636 Northern blotting Methods 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 2
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 description 1
- 101150028385 ATG2 gene Proteins 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102000005128 Alkaline Ceramidase Human genes 0.000 description 1
- 108010028303 Alkaline Ceramidase Proteins 0.000 description 1
- 102100035660 Glyceraldehyde-3-phosphate dehydrogenase, testis-specific Human genes 0.000 description 1
- 101001000892 Homo sapiens Glyceraldehyde-3-phosphate dehydrogenase, testis-specific Proteins 0.000 description 1
- 101000938391 Homo sapiens Transmembrane protein Proteins 0.000 description 1
- 101100005911 Mus musculus Cer1 gene Proteins 0.000 description 1
- 101100380548 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) apg-2 gene Proteins 0.000 description 1
- 102000006243 Neutral Ceramidase Human genes 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102000011971 Sphingomyelin Phosphodiesterase Human genes 0.000 description 1
- 108010061312 Sphingomyelin Phosphodiesterase Proteins 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 description 1
- DUYSYHSSBDVJSM-KRWOKUGFSA-N sphingosine 1-phosphate Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)COP(O)(O)=O DUYSYHSSBDVJSM-KRWOKUGFSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
- C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention relates to a ceramidase.
- Ceramidase cleaves ceramide and produces sphingosine, which is subsequently converted into sphingosine-1-phosphate.
- Various ceramidase activities have been described:
- WO 00/56891 relates to speculative human transmembrane proteins. There a sequence is disclosed which corresponds to a ceramidase, but without assigning functionality to it. Koch, Jürgen et al. in Journal of Biological Chemistr ⁇ (271) 33.110-33.115, Rosenberg a in proceedings of the Federation European by chemical society 1,980, L Babab Sama et al. in Journal of Biological Chemistry (274) pages 27,948-27,955, Jada Y. et al. in Journal of Biological Chemistry (270) pages 12,677 - 12,684 report on ceramidases and their characterization.
- ceramidase with the following structural motif is used
- Xl position is an aromatic amino acid (F, Y or W)
- all X2 positions are arbitrary, mutually independent amino acids and Z 1 and Z 2 are any polypeptides.
- the proteins claimed according to the invention contain the motif mentioned in claim 1. This also includes proteins that have been modified in the side chains. In particular phosphorylations, glycolizations, amidations and other derivatizations in the side chains.
- modifications in the primary structure can be used to produce fragments which also ensure the biological functions of the proteins according to the invention. These include, for example, fragmentations in the area around the motif claimed according to the invention, wherein correspondingly biologically active fragments can easily be determined by a person skilled in the art by appropriate experiments. These include, for example, Site Directed Mutagenesjs, which can be used to produce structural variants that also have biological activity. In terms of protein chemistry, exchanges of amino acids or sequences or motifs within the primary structure are also possible.
- exchanges are well known to those skilled in the art and include, for example, conservative exchanges in which, for example, serine is exchanged for threonine.
- Other groups known to those skilled in the art are of course also suitable as exchange candidates.
- the groups of non-polar amino acids, polar amino acids, aromatic amino acids can be exchanged with one another without profound changes in the biological function being expected.
- Part A shows that in a large number of human (tissue no ceramidase signal is visible.
- Part B shows that a strong signal is visible in skin RNA that is absent in the human cell lines shown.
- Ceramidase K2 shows the result of a quantitative PCR analysis of the skin-specific Ceramidase K1 and as a comparison of the Ceramidase K2.
- the level of expression of Ceramidase Kl in the skin is age-dependent, a stronger signal can be observed in the skin of a 68 year old person than in the skin of a 28 year old person. Ceramidase K2 shows no age dependency.
- transmembrane ceramidases are preferably transmembrane ceramidases.
- Preferred ceramidases have the following sequence: Ceramidase Kl (human protein) Seq. ID No 1,
- the invention also relates to nucleic acids which code for ceramidase, in particular with the sequence
- a nucleic acid that is complementary to these nucleic acids is also part of the invention.
- Another aspect of the invention is a pharmaceutical, cosmetic or diagnostic agent containing the ceramidase according to the invention or a nucleic acid according to the invention, the ceramidase Seq. ID No 2 or Seq. ID No 5 excluded.
- the medicinal, cosmetic and diagnostic agents are suitable for the diagnosis of diseases, for the treatment or prevention of diseases which are associated with a ceramidase defect, in particular in connection with diseases which are associated with impaired cell proliferation (for example cancer), diseases which are associated with a disruption of the ceramide layer of the skin such as neurodermatitis, eczema, psoriasis and for the targeted influencing of the permeability barrier by ceramidase or ceramidase activators, for example for the transcutaneous administration of substances.
- the gene for ceramidase K4 is located on chromosome 2 in the 2q33q34 range. This area also contains the gene of the skin disease "lamellar ichthyosis ICR2B".
- the ceramidase K4 according to the invention is particularly suitable for the diagnosis and therapy of this disease, with which it is probably causally connected.
- the invention also relates to a cell line which overexpresses the ceramidases according to the invention and a transgenic animal with overexpression or gene deficiency or gene defect for the ceramidases according to the invention.
- the Cdasel cDNA was amplified using PCR. 5 ⁇ g of human skin RNA that had previously been reverse transcribed served as a template. The following primers were used for amplification: cerl atg2 s: caagATGCCTAGCATCTTCGCC Seq. ID No 7 cert e2 as: caggtctcagcagtccttgtcatc Seq. ID No 14
- the amplified cDNA was subcloned and the sequence subsequently verified.
- the tissue distribution of the Cdasel was analyzed using the Northern blot technique.
- a commercially available blot (Clontech Laboratories Inc., Catalog #: 7780-1)
- a blot was produced from RNA from cell lines and human skin (1 ⁇ g poly A + RNA each).
- the first 668 bp of the cDNA was used as a probe.
- the cDNA fragment was radiolabelled. Hybridization took place overnight at 65 ° C.
- the radioactive Signals were measured using the Cyclone Storage Phosphor System (both from Packard Instrument Company, Dreieich) and evaluated using the Opti-Quant program.
- the blots were normalized with either ß-actin or GAPDH.
- the entire cDNA was cloned into a eukaryotic expression vector under the control of the CMV promoter.
- HEK293 cells were electroporated with the construct and subsequently selected with G418. Cell clones that survived the selection were examined for Cdasel overexpression.
- the level of expression in young and old skin was measured with the help of real time
- GAPDH served as standard.
- GAPDHS GAAGGTGAAGGTCGGAGT Seq. ID No 11
- GAPDHR GAAGATGGTGATGGGATTTC Seq. ID No 12
- GAPDHT CAAGCTTCCCGTTCTCAGCC [5 '] 6_FAM [3'] TAMRA Seq. ID No 13
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2001240552A AU2001240552A1 (en) | 2000-01-27 | 2001-01-27 | Ceramidase |
EP01911543A EP1250441A1 (de) | 2000-01-27 | 2001-01-27 | Ceramidase |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10003293.1 | 2000-01-27 | ||
DE10003293 | 2000-01-27 | ||
DE10011392 | 2000-03-09 | ||
DE10011392.3 | 2000-03-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001055408A1 true WO2001055408A1 (de) | 2001-08-02 |
Family
ID=26004037
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2001/000900 WO2001055408A1 (de) | 2000-01-27 | 2001-01-27 | Ceramidase |
Country Status (4)
Country | Link |
---|---|
US (1) | US20030185814A1 (de) |
EP (1) | EP1250441A1 (de) |
AU (1) | AU2001240552A1 (de) |
WO (1) | WO2001055408A1 (de) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007131720A1 (en) * | 2006-05-11 | 2007-11-22 | Cosmoferm B.V. | Improved production of sphingoid bases using genetically engineered microbial strains |
FR2924946A1 (fr) * | 2007-12-18 | 2009-06-19 | Oreal | Utilisation cosmetique de proteines de type ceramidase acide |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000056891A2 (en) * | 1999-03-22 | 2000-09-28 | Incyte Pharmaceuticals, Inc. | Human transmembrane proteins |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5506079A (en) * | 1994-02-28 | 1996-04-09 | Ricoh Company, Ltd. | Magnetic composition, magnetic toner and ink containing the magnetic composition |
US5945209A (en) * | 1996-11-07 | 1999-08-31 | Fuji Photo Film Co., Ltd. | Anti-reflection film and plasma display panel |
-
2001
- 2001-01-27 US US10/182,447 patent/US20030185814A1/en not_active Abandoned
- 2001-01-27 WO PCT/EP2001/000900 patent/WO2001055408A1/de not_active Application Discontinuation
- 2001-01-27 AU AU2001240552A patent/AU2001240552A1/en not_active Abandoned
- 2001-01-27 EP EP01911543A patent/EP1250441A1/de not_active Withdrawn
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000056891A2 (en) * | 1999-03-22 | 2000-09-28 | Incyte Pharmaceuticals, Inc. | Human transmembrane proteins |
Non-Patent Citations (9)
Title |
---|
DATABASE EMBL 1 November 1996 (1996-11-01), GAMPEL A ET AL: "LPG21P (ALKALINE CERAMIDASE YDC1P).", XP002168603 * |
DATABASE EMBL 14 December 1999 (1999-12-14), WATERSTON R H: "Homo sapiens chromosome 2 clone RP11-470J24, WORKING DRAFT SEQUENCE, 16 unordered pieces.", XP002168604 * |
DATABASE EMBL 29 February 1996 (1996-02-29), HILLIER L ET AL: "yw93h12.r1 Soares_placenta_8to9weeks_2NbHP8to9W Homo sapiens cDNA clone IMAGE:259847 5' similar to SW:YB33_YEAST P38298 HYPOTHETICAL 36.4 KD PROTEIN IN RPS101-RPS13 INTERGENIC REGION. [2] PIR:S46055 ;, mRNA sequence.", XP002152789 * |
DATABASE EMBL 8 October 1999 (1999-10-08), DOE JOINT GENOME INSTITUTE: "Homo sapiens chromosome 19 clone CTB-180A7, WORKING DRAFT SEQUENCE, 12 unordered pieces.", XP002152788 * |
EL BAWAB SAMER ET AL: "Purification and characterization of a membrane-bound nonlysosomal ceramidase from rat brain.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 274, no. 39, pages 27948 - 27955, XP002929691, ISSN: 0021-9258 * |
KOCH JUERGEN ET AL: "Molecular cloning and characterization of a full-length complementary DNA encoding human acid ceramidase: Identification of the first molecular lesion causing Farber disease.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 271, no. 51, 1996, pages 33110 - 33115, XP002152787, ISSN: 0021-9258 * |
PARMENTIER L ET AL: "Lamellar Ichthyosis: Further narrowing, physical and expression mapping of the chromosome 2 candidate locus.", EUROPEAN JOURNAL OF HUMAN GENETICS, vol. 7, no. 1, January 1999 (1999-01-01), pages 77 - 87, XP001002253, ISSN: 1018-4813 * |
ROSENBERG A: "PURIFICATION OF HUMAN BETA-GLUCOSYL CERAMIDASE FROM CULTURED CELLS FOR POTENTIAL ENZYME REPLACEMENT THERAPY IN GAUCHERS'S DISEASE", PROCEEDINGS OF THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES, 1980, XP000915137 * |
YADA Y ET AL: "PURIFICATION AND BIOCHEMICAL CHARACTERIZATION OF MEMBRANE-BOUND EPIDERMAL CERAMIDASES FROM GUINEA PIG SKIN (*)", JOURNAL OF BIOLOGICAL CHEMISTRY,THE AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, INC.,,US, vol. 270, no. 21, May 1995 (1995-05-01), pages 12677 - 12684, XP000937467, ISSN: 0021-9258 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007131720A1 (en) * | 2006-05-11 | 2007-11-22 | Cosmoferm B.V. | Improved production of sphingoid bases using genetically engineered microbial strains |
US8372595B2 (en) | 2006-05-11 | 2013-02-12 | Evonik Industries Ag | Method for obtaining a microbial strain for production of sphingoid bases |
FR2924946A1 (fr) * | 2007-12-18 | 2009-06-19 | Oreal | Utilisation cosmetique de proteines de type ceramidase acide |
WO2009077995A1 (en) * | 2007-12-18 | 2009-06-25 | L'oreal | Cosmetic use of acid ceramidase type proteins |
Also Published As
Publication number | Publication date |
---|---|
EP1250441A1 (de) | 2002-10-23 |
AU2001240552A1 (en) | 2001-08-07 |
US20030185814A1 (en) | 2003-10-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69820419T2 (de) | Klonierung und verwendung des lsr-rezeptors | |
DE69230993T3 (de) | Rekombinante viren vektoren zur expression in muskelzellen | |
EP1276889B1 (de) | Sleeping beauty, ein transposonvektor mit breitem wirtsbereich für die genetische transformation bei wirbeltieren | |
DE69733204T2 (de) | Neuartige vegf-ähnliche faktoren | |
EP0827537B1 (de) | Chromatin-regulatorgene | |
Siegfried et al. | Defeat, learned submissiveness, and analgesia in mice: effect of genotype | |
DE69932153T2 (de) | Phosphodiesterase 10 | |
DE69630442T2 (de) | Ein neuartiger wachstumsfaktor und eine genetische sequenz, die für diesen codiert | |
EP1021546A1 (de) | Neutrale sphingomyelinase | |
EP1250441A1 (de) | Ceramidase | |
WO2002100895A2 (de) | Antimikrobiell wirkendes peptid | |
DE60128009T2 (de) | Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma | |
WO2001055198A2 (de) | Haut- und magen-spezifischer sphingolipid-aktivator | |
DE69937191T2 (de) | Gen kodierend für organischen Aniontransporter | |
DE69838565T2 (de) | Nukleinsäuren von CIITA Genen | |
DE60131372T2 (de) | Sekretierte gruppe iii phospholipase a2 aus säugetieren | |
WO2001080871A2 (de) | Anwendung von guanylat-zyklase-c (gc-c) agonisten als insulinotrope faktoren zur behandlung von diabetes mellitus typ 2 | |
WO1999054448A2 (de) | Menschliche nukleinsäurefragmente, deren expression in uterusmyomgewebeerhoeht ist | |
WO2001012818A1 (de) | Neutrale hirn-sphingomyelinase | |
DE69832371T2 (de) | Varianten des neurotrophischen ziliarischen faktors mit erhöhter rezeptor-selektivität und verfahren zu deren auswahl | |
WO2001070951A2 (de) | Mittel zur diagnose und therapie viraler erkrankungen | |
DE60217081T2 (de) | Gen beteiligt an v(d)j rekombination und/oder dna reparatur | |
DE19910912C2 (de) | Neue Sequenzvarianten des menschlichen RET Protoonkogens und ihre Verwendung | |
EP1086220A2 (de) | Gdnf-kodierende dna, teile davon und gdnf-varianten | |
DE60117641T2 (de) | Modulierte sekretierte alkalische Phosphatase (SEAP) Reporter Gene und Polypeptide |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2001911543 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2001 554437 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10182447 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2001911543 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2001911543 Country of ref document: EP |